<p>启迪医疗系统公司（NYSE:INSP - 获取免费报告）周三股价创下 52 周新低，此前摩根大通将该股目标价从 67.00 美元下调至 54.00 美元。摩根大通目前对该股持中性评级。启迪医疗系统的股价最低曾达到 44.41 美元，最后交易价为 48.2390 美元，成交量为 4487693 股。该股此前收盘价为 54.84 美元。</p>
<ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
<p>其他一些股票分析师也对 INSP 发表了评论。Evercore 在周二的报告中将启迪医疗系统的目标价设定为 55.00 美元。Truist Financial 将启迪医疗系统的目标价从 64.00 美元下调至 50.00 美元，并在周二的报告中对该股给予 “持有” 评级。Robert W. Baird 将启迪医疗系统的目标价从 63.00 美元下调至 50.00 美元，并在周二的报告中对该股给予 “中性” 评级。瑞银集团在 2 月 13 日的报告中将启迪医疗系统的目标价设定为 67.00 美元。最后，Stifel Nicolaus 在周二的报告中将启迪医疗系统的目标价从 70.00 美元下调至 65.00 美元，并对该股给予 “买入” 评级。四位分析师对该股给予 “买入” 评级，十五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “持有”，共识目标价为 85.00 美元。</p>
<p><strong>查看我们最新的 INSP 股票报告</strong></p>
<h2>启迪医疗系统新闻摘要</h2>
<ul>
<li>启迪医疗上涨 15% 后突破，分析师称其为买入</li>
</ul>
<p>以下是本周影响启迪医疗系统的主要新闻：</p>
<ul>
<li>积极情绪：第一季度超出预期——报告每股收益 0.10 美元（预期为-0.28 美元）和收入 2.046 亿美元（预期约为 2 亿美元），显示基础业务仍然盈利。第一季度新闻稿</li>
<li>积极情绪：一些经纪商保持建设性立场（Stifel 维持 “买入”，瑞穗维持 “跑赢大盘”），即使在下调目标后，如果指导风险缓解，仍有潜在上行空间。分析师反应（Benzinga）</li>
<li>中性情绪：美国银行重申中性评级，目标价为 53 美元——这一适度谨慎的观点反映了市场的观望态度。美国银行重申</li>
<li>消极情绪：管理层将 2026 财年的指导下调至每股收益 0.75-1.25 美元和收入 8.25 亿-8.75 亿美元，而共识预期为每股收益约 1.99 美元和收入约 9.61 亿美元——大幅下调指导是主要的负面催化剂。2026 财年指导下调</li>
<li>消极情绪：公司提到报销/编码不确定性和 WISeR 项目带来的干扰，导致手术量减少——这些运营阻力可能会对近期收入恢复施加压力。报销与 WISeR 问题</li>
<li>消极情绪：多家经纪商下调目标价（摩根大通 67→54 美元；富国银行 70→56 美元；Truist 64→50 美元；Baird 63→50 美元），共识下调并增加了卖出压力，尽管仍有一些买入/跑赢大盘评级。分析师目标价变动（摩根大通/TickerReport）</li>
</ul>
<h2>机构投资者对启迪医疗系统的看法</h2>
<p>一些机构投资者最近调整了对该股的持有。Principal Financial Group Inc. 在第一季度将其在启迪医疗系统的股份增加了 1.0%。Principal Financial Group Inc. 目前拥有 126,788 股该公司股票，价值 6,540,000 美元，此前在上个季度又购买了 1,269 股。Fifth Third Bancorp 在第一季度将其在启迪医疗系统的股份增加了 1,794.4%。Fifth Third Bancorp 目前拥有 6,441 股该公司股票，价值 332,000 美元，此前在上个季度又购买了 6,101 股。纽约州教师退休系统在第一季度将其在启迪医疗系统的股份增加了 9.3%。纽约州教师退休系统目前拥有 23,599 股该公司股票，价值 1,217,000 美元，此前在上个季度又购买了 2,004 股。Y Intercept Hong Kong Ltd 在第一季度将其在启迪医疗系统的股份增加了 124.1%。Y Intercept Hong Kong Ltd 目前拥有 158,274 股该公司股票，价值 8,164,000 美元，此前在上个季度又购买了 87,639 股。最后，Leonteq Securities AG 在第一季度将其在启迪医疗系统的股份增加了 187.3%。Leonteq Securities AG 目前拥有 22,812 股该公司股票，价值 1,177,000 美元，此前在上个季度又购买了 14,873 股。机构投资者和对冲基金持有该公司 94.91% 的股份。</p>
<h2>启迪医疗系统股票表现</h2>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p>该公司的市值为 13.9 亿美元，市盈率为 10.74，市盈增长比率为 2.83，贝塔值为 0.83。该公司的 50 日移动平均价格为 56.51 美元，200 日移动平均价格为 79.43 美元。</p>
<p>启迪医疗系统（NYSE:INSP - 获取免费报告）最后一次发布季度财报是在 5 月 4 日，报告每股收益为 0.10 美元，超出共识预期的-0.28 美元 0.38 美元。该季度的收入为 2.0458 亿美元，而分析师预期为 2.0004 亿美元。启迪医疗系统的净利润率为 14.33%，股本回报率为 10.66%。启迪医疗系统的季度收入同比增长 1.6%。在去年同期，该公司每股收益为 0.10 美元。启迪医疗系统已将其 2026 财年的指导设定为 0.750-1.250 美元每股收益。分析师平均预测启迪医疗系统将在当前财年发布 1.82 美元每股收益。</p>
<h2>关于启迪医疗系统</h2>
<p>（获取免费报告）</p>
<p>启迪医疗系统公司是一家医疗科技公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品 Inspire® 系统，通过对舌下神经的定向刺激，在睡眠期间保持气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
<p>Inspire 系统由一个可植入的脉冲发生器、一个监测呼吸模式的传感导线和一个激活舌下神经的刺激导线组成。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比启迪医疗系统更好的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在启迪医疗系统吗？</h2>
<p>在考虑启迪医疗系统之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而启迪医疗系统并不在名单上。</p>
<p>尽管启迪医疗系统目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

启迪医疗

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>启迪医疗系统（NYSE:INSP）在摩根大通将其目标股价从 67 美元下调至 54 美元后，创下了新的 12 个月低点。该股最低交易价为 44.41 美元，收盘价为 48.24 美元，交易量为 4,487,693 股。分析师的评级各不相同，四位分析师推荐买入，十五位分析师建议持有。公司还大幅下调了 2026 财年的指引，原因是报销问题和运营挑战。机构投资者持有该股 94.91%，尽管近期评级下调，但仍反映出强烈的投资兴趣</p>

<p>Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report)'s share price hit a new 52-week low on Wednesday after JPMorgan Chase &amp; Co. lowered their price target on the stock from $67.00 to $54.00. JPMorgan Chase &amp; Co. currently has a neutral rating on the stock. Inspire Medical Systems traded as low as $44.41 and last traded at $48.2390, with a volume of 4487693 shares. The stock had previously closed at $54.84.</p>
<div class="lb-trans"><p>启迪医疗系统公司（NYSE:INSP - 获取免费报告）周三股价创下 52 周新低，此前摩根大通将该股目标价从 67.00 美元下调至 54.00 美元。摩根大通目前对该股持中性评级。启迪医疗系统的股价最低曾达到 44.41 美元，最后交易价为 48.2390 美元，成交量为 4487693 股。该股此前收盘价为 54.84 美元。</p>
</div><ul>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><ul>
<li>艾利 Lilly 股票上涨：GLP-1 Zepbound 目标睡眠呼吸暂停市场</li>
</ul>
</div><p>A number of other equities analysts have also commented on INSP. Evercore set a $55.00 price objective on shares of Inspire Medical Systems in a report on Tuesday. Truist Financial cut their price objective on shares of Inspire Medical Systems from $64.00 to $50.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday. Robert W. Baird cut their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday. UBS Group set a $67.00 price objective on shares of Inspire Medical Systems in a report on Friday, February 13th. Finally, Stifel Nicolaus cut their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a &#34;buy&#34; rating on the stock in a report on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $85.00.</p>
<div class="lb-trans"><p>其他一些股票分析师也对 INSP 发表了评论。Evercore 在周二的报告中将启迪医疗系统的目标价设定为 55.00 美元。Truist Financial 将启迪医疗系统的目标价从 64.00 美元下调至 50.00 美元，并在周二的报告中对该股给予 “持有” 评级。Robert W. Baird 将启迪医疗系统的目标价从 63.00 美元下调至 50.00 美元，并在周二的报告中对该股给予 “中性” 评级。瑞银集团在 2 月 13 日的报告中将启迪医疗系统的目标价设定为 67.00 美元。最后，Stifel Nicolaus 在周二的报告中将启迪医疗系统的目标价从 70.00 美元下调至 65.00 美元，并对该股给予 “买入” 评级。四位分析师对该股给予 “买入” 评级，十五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “持有”，共识目标价为 85.00 美元。</p>
</div><p><strong>View Our Latest Stock Report on INSP</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 INSP 股票报告</strong></p>
</div><h2>Inspire Medical Systems News Summary</h2>
<div class="lb-trans"><h2>启迪医疗系统新闻摘要</h2>
</div><ul>
<li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>启迪医疗上涨 15% 后突破，分析师称其为买入</li>
</ul>
</div><p>Here are the key news stories impacting Inspire Medical Systems this week:</p>
<div class="lb-trans"><p>以下是本周影响启迪医疗系统的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat consensus — reported $0.10 EPS (vs. est. -$0.28) and $204.6M revenue (vs. est. ~$200M), showing the underlying business still generates profitability. Q1 Press Release</li>
<li>Positive Sentiment: Some brokers kept constructive stances (Stifel maintained a &#34;buy&#34; and Mizuho an &#34;outperform&#34;) even after lowering targets, which provides potential upside if guidance risks ease. Analyst Reactions (Benzinga)</li>
<li>Neutral Sentiment: Bank of America reaffirmed a neutral rating with a $53 target — a modestly cautious view that mirrors the market’s wait‑and‑see stance. BofA Reaffirmation</li>
<li>Negative Sentiment: Management cut FY‑2026 guidance to $0.75–$1.25 EPS and $825M–$875M revenue vs. consensus ~ $1.99 EPS and ~$961M revenue — the sizable guidance cut is the primary negative catalyst. FY‑2026 Guidance Cut</li>
<li>Negative Sentiment: Company cited reimbursement/coding uncertainty and disruptions from the WISeR program that have reduced procedure volumes — operational headwinds that could pressure near‑term revenue recovery. Reimbursement &amp; WISeR Issues</li>
<li>Negative Sentiment: Multiple brokers cut price targets (JPMorgan $67→$54; Wells Fargo $70→$56; Truist $64→$50; Baird $63→$50), shifting consensus lower and adding selling pressure despite some remaining buy/outperform ratings. Analyst PT Moves (JPMorgan/TickerReport)</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度超出预期——报告每股收益 0.10 美元（预期为-0.28 美元）和收入 2.046 亿美元（预期约为 2 亿美元），显示基础业务仍然盈利。第一季度新闻稿</li>
<li>积极情绪：一些经纪商保持建设性立场（Stifel 维持 “买入”，瑞穗维持 “跑赢大盘”），即使在下调目标后，如果指导风险缓解，仍有潜在上行空间。分析师反应（Benzinga）</li>
<li>中性情绪：美国银行重申中性评级，目标价为 53 美元——这一适度谨慎的观点反映了市场的观望态度。美国银行重申</li>
<li>消极情绪：管理层将 2026 财年的指导下调至每股收益 0.75-1.25 美元和收入 8.25 亿-8.75 亿美元，而共识预期为每股收益约 1.99 美元和收入约 9.61 亿美元——大幅下调指导是主要的负面催化剂。2026 财年指导下调</li>
<li>消极情绪：公司提到报销/编码不确定性和 WISeR 项目带来的干扰，导致手术量减少——这些运营阻力可能会对近期收入恢复施加压力。报销与 WISeR 问题</li>
<li>消极情绪：多家经纪商下调目标价（摩根大通 67→54 美元；富国银行 70→56 美元；Truist 64→50 美元；Baird 63→50 美元），共识下调并增加了卖出压力，尽管仍有一些买入/跑赢大盘评级。分析师目标价变动（摩根大通/TickerReport）</li>
</ul>
</div><h2>Institutional Investors Weigh In On Inspire Medical Systems</h2>
<div class="lb-trans"><h2>机构投资者对启迪医疗系统的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. raised its stake in shares of Inspire Medical Systems by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company's stock valued at $6,540,000 after purchasing an additional 1,269 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Inspire Medical Systems by 1,794.4% in the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company's stock valued at $332,000 after purchasing an additional 6,101 shares in the last quarter. New York State Teachers Retirement System raised its stake in shares of Inspire Medical Systems by 9.3% in the 1st quarter. New York State Teachers Retirement System now owns 23,599 shares of the company's stock valued at $1,217,000 after purchasing an additional 2,004 shares in the last quarter. Y Intercept Hong Kong Ltd raised its stake in shares of Inspire Medical Systems by 124.1% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company's stock valued at $8,164,000 after purchasing an additional 87,639 shares in the last quarter. Finally, Leonteq Securities AG raised its stake in shares of Inspire Medical Systems by 187.3% in the 1st quarter. Leonteq Securities AG now owns 22,812 shares of the company's stock valued at $1,177,000 after purchasing an additional 14,873 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对该股的持有。Principal Financial Group Inc. 在第一季度将其在启迪医疗系统的股份增加了 1.0%。Principal Financial Group Inc. 目前拥有 126,788 股该公司股票，价值 6,540,000 美元，此前在上个季度又购买了 1,269 股。Fifth Third Bancorp 在第一季度将其在启迪医疗系统的股份增加了 1,794.4%。Fifth Third Bancorp 目前拥有 6,441 股该公司股票，价值 332,000 美元，此前在上个季度又购买了 6,101 股。纽约州教师退休系统在第一季度将其在启迪医疗系统的股份增加了 9.3%。纽约州教师退休系统目前拥有 23,599 股该公司股票，价值 1,217,000 美元，此前在上个季度又购买了 2,004 股。Y Intercept Hong Kong Ltd 在第一季度将其在启迪医疗系统的股份增加了 124.1%。Y Intercept Hong Kong Ltd 目前拥有 158,274 股该公司股票，价值 8,164,000 美元，此前在上个季度又购买了 87,639 股。最后，Leonteq Securities AG 在第一季度将其在启迪医疗系统的股份增加了 187.3%。Leonteq Securities AG 目前拥有 22,812 股该公司股票，价值 1,177,000 美元，此前在上个季度又购买了 14,873 股。机构投资者和对冲基金持有该公司 94.91% 的股份。</p>
</div><h2>Inspire Medical Systems Stock Performance</h2>
<div class="lb-trans"><h2>启迪医疗系统股票表现</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p>The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 10.74, a price-to-earnings-growth ratio of 2.83 and a beta of 0.83. The business's 50 day moving average price is $56.51 and its 200-day moving average price is $79.43.</p>
<div class="lb-trans"><p>该公司的市值为 13.9 亿美元，市盈率为 10.74，市盈增长比率为 2.83，贝塔值为 0.83。该公司的 50 日移动平均价格为 56.51 美元，200 日移动平均价格为 79.43 美元。</p>
</div><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.66%. Inspire Medical Systems's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts forecast that Inspire Medical Systems, Inc. will post 1.82 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>启迪医疗系统（NYSE:INSP - 获取免费报告）最后一次发布季度财报是在 5 月 4 日，报告每股收益为 0.10 美元，超出共识预期的-0.28 美元 0.38 美元。该季度的收入为 2.0458 亿美元，而分析师预期为 2.0004 亿美元。启迪医疗系统的净利润率为 14.33%，股本回报率为 10.66%。启迪医疗系统的季度收入同比增长 1.6%。在去年同期，该公司每股收益为 0.10 美元。启迪医疗系统已将其 2026 财年的指导设定为 0.750-1.250 美元每股收益。分析师平均预测启迪医疗系统将在当前财年发布 1.82 美元每股收益。</p>
</div><h2>About Inspire Medical Systems</h2>
<div class="lb-trans"><h2>关于启迪医疗系统</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.</p>
<div class="lb-trans"><p>启迪医疗系统公司是一家医疗科技公司，专注于用于治疗阻塞性睡眠呼吸暂停（OSA）的可植入神经刺激设备。该公司的旗舰产品 Inspire® 系统，通过对舌下神经的定向刺激，在睡眠期间保持气道通畅，为对持续正压呼吸机（CPAP）设备不耐受或管理不当的患者提供了一种替代疗法。</p>
</div><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p>
<div class="lb-trans"><p>Inspire 系统由一个可植入的脉冲发生器、一个监测呼吸模式的传感导线和一个激活舌下神经的刺激导线组成。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Inspire Medical Systems</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比启迪医疗系统更好的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在启迪医疗系统吗？</h2>
</div><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑启迪医疗系统之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而启迪医疗系统并不在名单上。</p>
</div><p>While Inspire Medical Systems currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管启迪医疗系统目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Inspire Medical Systems (NYSE:INSP) Reaches New 12-Month Low on Analyst Downgrade

Market Beat

摩根大通

礼来

Evercore

Truist Financial

瑞银集团

Stifel Financial

瑞穗金融集团

Mizuho Financial Group, Inc.

美国银行

富国银行

信安金融

五三银行

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

五三银行-存托优先股Series K

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

五三银行-Series A

启迪医疗系统（NYSE:INSP）因分析师下调评级而创下 12 个月新低